Insulin Glargine

BreastfeedingPediatric
  • TRADE NAMES: Basaglar (Lilly); Lantus (Sanofi-Aventis); Soliqua (Sanofi-Aventis)
  • INDICATIONS: Diabetes (Type I or II)
  • CLASS: Hormone analog, polypeptide
  • HALF-LIFE: N/A
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

ACE inhibitors, Albuterol, Alcohol, Beta blockers, Clonidine, Clozapine, Corticosteroids, Danazol, Disopyramide, Diuretics, Epinephrine, Estrogens, Fibrates, Fluoxetine, Glucagon, Guanethidine, Isoniazid, Lithium, MAO inhibitors, Niacin, Olanzapine, Oral antidiabetic products, Oral Contraceptives, Pentamidine, Pentoxifylline, Phenothiazine derivatives, Pramlintide, Propoxyphene, Propranolol, Protease inhibitors, Reserpine, Salicylates, Somatostain analogs, Somatropin, Sulfonamide antibiotics, Terbutaline, Thyroid hormones

PREGNANCY CATEGORY: C

Soliqua is insulin glargine and lixisenatide; various forms of insulin are available - see other insulin profiles for reaction details.

Our database has 33 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of insulin glargine in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 05/25/2020

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top